The P2RY1 antibody targets the P2Y1 receptor, a G protein-coupled receptor (GPCR) that binds extracellular adenosine triphosphate (ATP) and its analogs. P2Y1 is widely expressed in various tissues, including platelets, smooth muscle cells, and the nervous system. It plays a critical role in platelet activation, neurotransmission, and vascular tone regulation by coupling with Gq proteins to activate phospholipase C (PLC), triggering intracellular calcium release and downstream signaling. Dysregulation of P2Y1 is linked to thrombotic disorders, inflammation, and neurodegenerative diseases.
P2RY1 antibodies are essential tools for studying receptor localization, expression levels, and functional mechanisms in both physiological and pathological contexts. They are utilized in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate P2Y1's role in platelet aggregation, synaptic plasticity, or immune responses. Additionally, some antibodies serve as antagonists to inhibit P2Y1 activity, aiding in therapeutic research for conditions like stroke or atherosclerosis. Recent studies also explore P2Y1's involvement in cancer progression, highlighting the antibody's potential in oncology research. As a key reagent, P2RY1 antibodies bridge molecular insights and translational applications, advancing drug discovery and mechanistic understanding of purinergic signaling pathways.